Ernexa Therapeutics Inc.
Income Statement
| Line Item | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Sep 2023 | Mar 2023 | Sep 2022 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0K | $487.0K | $47.0K | $47.0K | $51.0K | $0 | $0 | $1.2M |
| Cost of Revenue | $0 | $-60.0K | $95.0K | $61.0K | $120.0K | $50.0K | $0 | — |
| Gross Profit | $1.0K | $547.0K | $-48.0K | $-14.0K | $-69.0K | $-50.0K | $0 | — |
| Gross Margin | 100.0% | 112.3% | -102.1% | -29.8% | -135.3% | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $1.5M | $3.4M | $3.9M | $4.3M | $4.0M | $3.6M | $3.3M | $1.3M |
| Operating Income | $-2.7M | $-2.3M | $-4.9M | $-5.8M | $-5.5M | $-5.3M | $-8.3M | $-2.2M |
| Operating Margin | -269,700.0% | -463.9% | -10,491.5% | -12,312.8% | -10,794.1% | — | — | -187.8% |
| Interest Expense | — | — | — | $407.0K | — | $0 | — | — |
| Pretax Income | $-5.7M | $-26.6M | $-5.5M | $-6.6M | $-5.6M | $-5.4M | $-7.3M | $-2.5M |
| Income Tax Expense | $11.0K | $12.0K | $3.0K | $4.0K | $-8.0K | $5.0K | $5.0K | $23.0K |
| Net Income | $-5.8M | $-26.6M | $-5.5M | $-6.6M | $-5.6M | $-5.4M | $-7.3M | $-2.2M |
| Net Margin | -575,900.0% | -5,462.8% | -11,763.8% | -14,142.6% | -10,962.7% | — | — | -188.8% |
| EPS (Basic) | $5.90 | $-10.53 | $-2.19 | $-0.18 | $-0.15 | $-0.15 | $-0.36 | $-0.02 |
| EPS (Diluted) | $5.90 | $-10.53 | $-2.19 | $-0.18 | $-0.15 | $-0.15 | $-0.36 | $-0.02 |
| Shares Outstanding (Basic) | 6.4M | 2.5M | 2.5M | 37.9M | 37.9M | 35.9M | 20.6M | 123.1M |
| Shares Outstanding (Diluted) | 6.4M | 2.5M | 2.5M | 37.9M | 37.9M | 35.9M | 20.6M | 123.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |